Business
27 May, 2026
Tata 1mg turns EBITDA positive across core units as diagnostics crosses Rs 600 cr in ARR
Business To Business, New Delhi, 27th May, 2026: Tata 1mg has announced that it became EBITDA positive across all its established businesses during FY26, marking a significant profitability milestone for the company as it expands its presence in online pharmacy, diagnostics, and speciality healthcare services.
The company said its diagnostics division achieved:
- An annualised revenue run rate exceeding ₹600 crore
- More than 40% year-on-year growth
- Sustained double-digit EBITDA margins
Tata 1mg has been rapidly scaling its diagnostics network and currently operates:
- 19 NABL-accredited laboratories
- Services across 70 cities in India
Its National Reference Lab has also received accreditation from the College of American Pathologists (CAP), an internationally recognised benchmark for laboratory quality standards.
The company’s growth reflects increasing adoption of:
- Online medicine delivery
- At-home diagnostic testing
- Digital healthcare consultations
- Preventive healthcare services
Backed by Tata Digital, Tata 1mg competes in India’s rapidly expanding digital health sector alongside platforms offering e-pharmacy and diagnostic services.
The EBITDA-positive performance suggests improving operational efficiency and scale advantages as India’s digital healthcare market continues to grow with rising internet penetration, health awareness, and demand for convenient healthcare access.